Market Overview

Dr. Reddy's Laboratories Announces the Launch of Hervycta® (trastuzumab biosimilar) in India

Share:

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) announced
today that it has launched Hervycta® (trastuzumab), a
biosimilar of Roche's Herceptin®, in India, indicated for the
treatment of HER2-positive cancers (early breast cancer, metastatic
breast cancer and metastatic gastric cancer).

Dr. Reddy's Hervycta® is available in strengths of 150mg and
440mg multiple dose vials.

Commenting on the launch, MV Ramana, CEO-Branded Markets (India and
Emerging Markets), Dr. Reddy's Laboratories, said, "We strive every day
to do what matters most for patients. Hervycta® is a step
forward in our effort to accelerate access to cancer patients in India,
in the Oncology biosimilar space."

Dr. Raymond De Vré, Senior Vice President and Head, Biologics, Dr.
Reddy's Laboratories, added, "The launch of Hervycta® will
immensely benefit women in India who are suffering from HER2-positive
breast cancer and are in need of access to high quality, affordable and
innovative medicines."

Herceptin® (marketed as Herclon™ in India) and its
biosimilars had India sales of approximately INR 290 Crore MAT for the
most recent twelve months ending in December 2017, according to Ipsos*.

Dr. Reddy's currently has four biosimilar products commercialized in
India and various emerging markets, and an active pipeline of several
biosimilar products in the oncology and immunology space.

*Ipsos India Tandem Oncology Monitor 2017

About Biosimilars
Biosimilarity means1:

That the biological product is highly similar to the reference product
notwithstanding minor differences in clinically inactive components; and,

There are no clinically meaningful differences between the biological
product and the reference product in terms of the safety, purity and
potency of the product.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy's
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management's current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words "may", "will", "should", "expects",
"plans", "intends", "anticipates", "believes", "estimates", "predicts",
"potential", or "continue" and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to, without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency/severity of insured loss events;
(ii) mortality and morbidity levels and trends; (iii) changing levels of
competition and general competitive factors; (iv) changes in laws and
regulations and in the policies of central banks and/or governments; and
(v) the impact of acquisitions or reorganization, including related
integration issues.

The company assumes no obligation to update any information contained
herein.

View Comments and Join the Discussion!